RELMADA THERAPEUTICS, INC. — Director's Dealing 2017

Oct 23, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2017-10-20

Reporting Person: TRAVERSA SERGIO (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-19	Options to purchase common stock	$0.81	A	850000	Acquired	2027-10-20	Common stock (850000)	Direct

Footnotes

F1: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant.